Literature DB >> 20621835

Alterations of the Wnt/beta-catenin pathway and its target genes for the N- and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice.

S Portal-Núñez1, D Lozano, L Fernández de Castro, A R de Gortázar, X Nogués, P Esbrit.   

Abstract

Type 1 diabetes mellitus (T1D) is associated with bone loss. Given that the Wnt/beta-catenin pathway is a major regulator of bone accrual, we assessed this pathway in mice with streptozotozin-induced T1D. In diabetic mouse long bones, we found alterations favouring the suppression of this pathway by using PCR arrays and beta-catenin immunostaining. Downregulation of sclerostin, an inhibitor of this pathway, also occurred, and related to increased osteocyte apoptosis. Our data show that both N- and C-terminal parathyroid hormone-related peptide fragments might exert osteogenic effects in this setting by targeting several genes of this pathway and increasing beta-catenin in osteoblastic cells. Copyright 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20621835     DOI: 10.1016/j.febslet.2010.05.047

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

1.  Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.

Authors:  Lindsay M Coe; Srinivasan Arjun Tekalur; Yutian Shu; Melissa J Baumann; Laura R McCabe
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

Review 2.  Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts.

Authors:  Evangelia Kalaitzoglou; Iuliana Popescu; R Clay Bunn; John L Fowlkes; Kathryn M Thrailkill
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

Review 3.  Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition.

Authors:  S Epstein; G Defeudis; S Manfrini; N Napoli; P Pozzilli
Journal:  Osteoporos Int       Date:  2016-03-15       Impact factor: 4.507

Review 4.  Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice.

Authors:  V V Zhukouskaya; C Eller-Vainicher; A P Shepelkevich; Y Dydyshko; E Cairoli; I Chiodini
Journal:  J Endocrinol Invest       Date:  2015-04-12       Impact factor: 4.256

5.  Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.

Authors:  C Tsentidis; D Gourgiotis; L Kossiva; A Marmarinos; A Doulgeraki; K Karavanaki
Journal:  Osteoporos Int       Date:  2016-10-20       Impact factor: 4.507

Review 6.  Effects of diabetes on osteocytes.

Authors:  Japneet Kaur; Sundeep Khosla; Joshua N Farr
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2022-06-24       Impact factor: 3.626

7.  Parathyroid hormone-related protein activates Wnt signaling to specify the embryonic mammary mesenchyme.

Authors:  Minoti Hiremath; Pamela Dann; Jennifer Fischer; Daniela Butterworth; Kata Boras-Granic; Julie Hens; Joshua Van Houten; Wei Shi; John Wysolmerski
Journal:  Development       Date:  2012-10-03       Impact factor: 6.868

Review 8.  Exploiting the WNT Signaling Pathway for Clinical Purposes.

Authors:  Mark L Johnson; Robert R Recker
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

9.  Treatment with N- and C-terminal peptides of parathyroid hormone-related protein partly compensate the skeletal abnormalities in IGF-I deficient mice.

Authors:  Lourdes Rodríguez-de la Rosa; Ana López-Herradón; Sergio Portal-Núñez; Silvia Murillo-Cuesta; Daniel Lozano; Rafael Cediel; Isabel Varela-Nieto; Pedro Esbrit
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

10.  Interruption of Wnt signaling in Müller cells ameliorates ischemia-induced retinal neovascularization.

Authors:  Kelu Kevin Zhou; Siribhinya Benyajati; Yun Le; Rui Cheng; Wenbo Zhang; Jian-xing Ma
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.